CYP2U1

Across TCGA pan-cancer cohorts, CYP2U1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CYP2U1 data layer compared with 26 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CYP2U1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CYP2U1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, LSCC, and LUAD are the cancer types where CYP2U1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	III,IV	0.947	0.500	.003	21	view →
LSCC	DFS	Tertile	All	0.624	0.884	.018	11	view →
LUAD	OS	Tertile	II,III,IV	0.776	0.441	.026	7	view →
OV	DFS	Median	All	0.630	0.940	.019	4	view →
UCEC	DFS	Median	III,IV	0.256	0.823	.026	4	view →
GBM	OS	Tertile	All	0.597	0.920	.034	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CYP2U1–PDAC (DFS)

Open the PDAC breakdown →